Twenty Years of Pills, the Worm Returns

Schistosomiasis is endemic in 78 countries, affecting ~151 million people with 12,858 deaths and 1.7 million DALYs in 2021. Mass drug administration (MDA) with praziquantel has been the primary control strategy for two decades, but it is fundamentally a morbidity control tool, not an elimination tool. Praziquantel kills adult worms but cannot kill developing juvenile stages, does not induce protective immunity, and prevalence can rebound to pre-treatment levels within 6-8 months after administration. Despite sustained annual MDA, persistent transmission hotspots remain and some areas have seen re-emergence. A vaccine is needed to achieve the WHO's 2030 elimination target, and the WHO's 2024 Vaccine Value Profile defines the requirements, but only four candidates have reached clinical trials and only one (Bilhvax) reached Phase 3 — where it failed.

Africa bears 84% of schistosomiasis prevalence, 88% of DALYs, and 87% of deaths. Peak burden falls on ages 15-29 — the most economically productive age group. Three species affect humans: *S. mansoni* (intestinal, Africa/Americas), *S. haematobium* (urogenital, Africa/Middle East), and *S. japonicum* (intestinal, Asia). Urogenital schistosomiasis is associated with increased HIV susceptibility, infertility, and bladder cancer. The complete reliance on a single drug (praziquantel) creates resistance risk — reports of systematic misuse of human praziquantel in livestock raise the specter of resistance emergence, which would be catastrophic given no backup drug exists.

Annual MDA programs reach millions of school-age children but face fundamental biological limitations: praziquantel has no activity against immature worms (4-6 week development period means recent infections are untreated), does not prevent reinfection, and even at maximum frequency cannot reduce prevalence enough in high-transmission areas to interrupt transmission. Community-wide MDA (adults + children) outperforms school-based MDA but still cannot eliminate transmission alone. WASH (water, sanitation, hygiene) interventions and snail control are complementary but insufficient without reduced susceptibility to reinfection. Bilhvax (Sh28GST), the most advanced vaccine candidate, reached Phase 3 but demonstrated insufficient efficacy. The three main challenges for schistosomiasis vaccines are: (1) identifying antigens that induce sterilizing or transmission-reducing immunity, (2) the IgE hypersensitivity risk in previously exposed populations, and (3) the need for vaccines effective against multiple schistosome species.

The WHO Vaccine Value Profile specifies: >=75% reduction in morbidity and transmission (preferred), 2-dose parenteral administration, >=2-3 years duration of protection, compatible with praziquantel MDA co-administration, storage at -20 to 4 degrees C, and cost <$1/dose. SchistoShield (Sm-p80 + GLA-SE adjuvant) is the most advanced current candidate: >90% efficacy against worms in baboon models, 35-fold decrease in fecal egg excretion, cross-protection against *S. haematobium*, Phase 1 completed in the US (2024) with no serious adverse events, and Phase 1b initiated in Madagascar and Burkina Faso (November 2023). Modeling shows vaccination combined with MDA provides greater benefits than either alone, with duration of protection being the most important variable.

A team could build a mathematical transmission model comparing elimination timelines under four strategies: MDA alone, MDA + WASH, MDA + vaccination (varying efficacy and duration of protection), and all three combined — parameterized for a high-transmission African setting. This would quantify what vaccine efficacy threshold would make elimination achievable by 2030 and how sensitive that timeline is to duration of protection. Alternatively, a team could analyze the Sm-p80 Phase 1 immunogenicity data (publicly available) to characterize the antibody response kinetics and predict duration of protection using mathematical modeling of immune waning. Relevant disciplines: epidemiological modeling, parasitology, immunology, global health policy.